Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australia has led the world in the research and development of this scan using a relatively novel radiotracer, known as PSMA PET/CT. The availability of funding for PSMA PET/CT scans is a major win for patients, who until now have either paid for these tests themselves or found the scans unobtainable because of the cost. The Australasian Association of Nuclear Medicine Specialists (AANMS) welcomed the MBS funding which it says will help improve outcomes for thousands of men with a higher risk prostate cancer. “PSMA PET/CT imaging enables highly specific detection of tumour sites throughout the body with far greater sensitivity compared to other conventional scans. This enables doctors to make more accurate
diagnoses than is currently possible with other MBS-funded scans, and which in turn can be lifesaving for some patients,” said AANMS President, Associate Professor Sze Ting Lee.
The AANMS has worked closely with partners to achieve this important milestone in the diagnosis and treatment of prostate cancer.
“We would like to acknowledge the work of Dr Robert Ware from Cyclotek in generating the original funding application and their ongoing support in steering the application with AANMS during the tenure of my predecessor, Dr Geoff Schembri. We also extend our thanks to all those who supported the application, including AstraZeneca who sponsored the submission,” Associate Professor Lee said.
With funding now available, AANMS will work closely with other key stakeholders to ensure that patients are appropriately referred for these tests.
Australian Health Journal spoke with Associate Professor Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
About AANMS
The AANMS is a peak body representing medical practitioners working in the field of nuclear medicine diagnosis and therapy. It works to promote and advance the clinical practice of nuclear medicine, which can be used to both diagnose and treat patients with a range of health conditions including the leading causes of death in Australia; cancer, dementia, heart and lung diseases; as well as renal, endocrine and paediatric disorders. Together with government and other stakeholders, AANMS is working to build a strong and sustainable nuclear medicine sector in Australia in order to optimise health outcomes for Australia patients.
-
Hair’s-breadth endoscopes to detect plaque
This coming World Heart Day (29th September 2021), Australian Health Journal’s People in Health Care series, releases a segment on Dr Jiawen Li.
Dr Jiawen Li is an inventor and highly adaptable engineer leading the intravascular imaging program at the Institute of Photonics and Advanced Sensing (IPAS). She has developing an imaging device can be inserted into blood vessels to provide high quality 3D images to help scientists better understand the causes of heart attack and heart disease progression, and could lead to improved treatment and prevention.
-
Implementing improvements in referral management and demand
Nalani Cox joined Gold Coast Health in 2019 as a Nurse Manager focused on improving referral management processes within the outpatient environment through the implementation of the Clinical Prioritisation Criteria. This work became a focus point for the organisation in 2020 when Nalani led an organisational wide change project introducing Smart Referrals, Refer Your Patient website and HealthPathways which has culminated in her position as the ADON of the Referral Strategy and Performance Department.
-
The Case for Embedded Pharmacy in Residential Aged Care
Embedded pharmacy in residential aged care has been successful in South Australia at the Tanunda Lutheran Home in the Barossa Valley. Julian Soriano talks about his pharmacy role in medication management and medication safety to deliver the best clinical care for residents.
In this segment, Julian talks about the traditional pharmacy model serving residential aged care and the limitations of the imprest process for dispensing medication. Soon into the project he saw the collaboration required with GPs and onsite nurses in dispensing medication for residents in end-of-life or palliative care. Julian sees the imprest process unable to support end-of-life residents, even being able to check the availability of medication.
But what most may not be aware of, is his rapid growth since starting the business in 2013 having just been in health care a few years earlier. Being part of a 2nd generation health care family, Shawn learnt from his father on site and at trade show visits overseas. Prior to HPA, he spent 2 years working in fit-outs of operating theatres, neo-natal and general population ICU, throughout being more fascinated with what he saw.
